139 Scientific Report 2011

SHARED RESEARCH RESOURCES

Cardiology

Tobacco Control

Clinical Psychology

Medical Statistics, Biometry, and Bioinformatics

Clinical Epidemiology and Trial Organization

Tissue Bank

Functional Genomics Core Facility

Cancer Proteomics-Molecular Mechanisms

140Shared Research Resources

cardiology

HEAD Patrizia Piotti, MD

CLINICAL RESEARCH STAFF Carlo Materazzo, MDEnzo Viggiano, MD Costanza Mantovani, MD Patrizia Greco, MD

POSTDOCTORAL FELLOWIvan Moschetti, MD

NURSES Sabrina Barrotta, Graziella Borlenghi, RosellaMurru, Luisa Sala, Maria Nunziata Depetro

ADMINISTRATIVE PERSONNELMaria Grazia Marchetti, Rosanna Villani

The Cardiology Unit carries out activity mainly concern-ing the preoperative evaluation of surgical patients, tightlycollaborating with anesthesiologists, thoracic and abdomi-nal surgeons in order to reduce preoperative risk andmanage complications. Meanwhile, evaluation and consul-tation support is also carried out for patients of BestaNeurological Institute. The Cardiology Unit, among itsmain obligations, performs general cardiological evalua-

tion of all candidates for chemo-radiotherapy treatment,with the aim of monitoring potential cardiovascular toxic-ity related to antineoplastic treatments: early recognition,diagnosis, and therapy Several Phase II and Phase III clini-cal studies have been carried out during 2011, withregular, mandatory, cardiological surveillance for possiblecardiotoxicity of new experimental drugs. Keywords: preoperative evaluation, cardiotoxicity, experimental drugs

surveillance

RELEVANT NOTES

Collaborations

Patrizia Piotti was an invited supervisor atSymphosium Cardio-Oncologia: Follow-upecocardiografico in soggetti trattati conchemioterapia: interrompere? Quando? XVCongresso Nazionale Ecocardiografia 2011, Naples,14-16 April 2011. Carlo Materazzo, Teacher of theECM course “Le indicazioni cliniche el’appropriatezza delle richieste: Valutazione clinicadel dosaggo delle troponine convenzionali e ad altasensibilità” IRCCS Foundation Neurologic InstituteC Besta. Milan, 25 Nov 2011. Patrizia Piotti andCarlo Materazzo: Co-founding members ofEchocardio-Oncology Group of Italian

Cardiovascular Echocardiography Society (SIEC),established in March 2010

Publications

Boccardi L.,Cardinale D., Civelli M., Lestuzzi C.,Materazzo C., Maurea N., Monte I., Oliva S., PiottiP., Quattrocchi G., Rossi E., Toglia G., Gruppo diStudio di Ecocardio-Oncologia della Società Italianadi Ecografia Cardiovascolare (SIEC), Coordinatore :Prof Pezzano A. (SIEC Milano): ApproccioCardiologico al paziente sottoposto a trattamentoantitumorale. Documento primo. J CardiovascEchography. 2011; 21: 31-41. Di Salvo G., Di BelloV., Salustri A., Antonini Canterin F., La Carrubba S.,Materazzo C., Badano L., Caso P., Pezzano A.,Calabrò R., Carerj S., on behalf of the Research

Group of the Italian Society of CardiovascularEchography (SIEC). The prognostic value of earlyleft ventricular longitudinal systolic dysfunction inasymptomatic subjects with cardiovascular riskfactors. Clin Cardiol. 2011; 34: 500-6. Di Salvo G.,Di Bello V., Salustri A., Antonini-Canterin F., LaCarrubba S., Materazzo C., Badano L., Caso P.,Pezzano A., Calabrò R., Carerj S., on behalf of theResearch Group of the Italian Society ofCardiovascular Echography (SIEC). Early leftventricular longitudinal systolic dysfunction andcardiovascular risk factors in 1,371 asymptomaticsubjects with normal ejection fraction: a tissueDoppler study. Echocardiography 2011; 28: 268-75.

141 Scientific Report 2011

tobacco control

HEAD Roberto Boffi, MD

EXTERNAL CONSULTANTSPaolo Pozzi, MD Giovanni Invernizzi, MD Ario Alberto Ruprecht Elena Munarini, PsyD Chiara Marabelli, PsyD Micaela Lina, PsyD

Clinical activity of the Tobacco Control Unit (TCU) isdevoted to smoking cessation (SC) programs: in 11 yearsof activity, the Unit was able to enroll 2200 smokers withan average cessation or reduction of 40%, in agreementwith guideline data. At the end of 2011pharmacogenomic study of smoking cessation was initi-ated in smokers treated with antismoking therapies. Aremarkable proportion of clinical activity (10%) isdevoted to the health of passive smokers. In 2006 westarted a comprehensive project aimed to offer to allinpatient smokers minimal advice and a SC program. Todate we have interviewed about 500 patients. Educationalactivities of TCU address to smoking policy at the work-place, to educational programs in schools, and to lobbyactivities against tobacco smoke. TCU helped 20 compa-nies in the implementation of a smoke-free workplace,while 40 schools are engaged in educational anti-smokingprograms for children and teachers. Educational activitiesin schools is still a major activity of the TCU; in fact, during

this school year it started the project “La scuola dellasalute” in collaboration with MIUR and Chiamamilano topromote healthy lifestyles among young people. We arealso teaching smoking cessation and tobacco marketingto degree programs in medicine, nursing, and pharmacyof the University of Milan since 2003. Another importantproject was initiated in collaboration with Local HealthAuthorities (Assessorato alla Salute del Comune diMilano) and AFM S.p.A. to bring in 5 community pharma-cies in Milan with new antismoking centers. For thispurpose, 15 hours of training for 10 selected pharmacists,2 for every pharmacy, edited by TCU, has beenperformed. Because of the educational importance ofexplaining the environmental health risks linked totobacco smoke, a research laboratory section for thestudy of ETS was implemented in 2001. The laboratoryimplemented several innovative research programs with anumber of scientific articles published. Keywords: smoking cessation, prevention, tobacco research

RELEVANT NOTES

Collaborations

Società Italiana di Medicina Generale Dipartimentodi Prevenzione Regione Veneto Respiratory Unit,Brompton Hospital, London, UK South WesternUniversity, Los Angeles, USA Cornell University,New York, USA

Publications

Mazza R., Lina M., Invernizzi G., Pierotti M., DeMarco C., Borreani C., Boffi R. The gap betweentobacco treatment guidelines, health service

organization, and clinical practice in comprehensivecancer centres. J Oncol. 2011; 2011: 145617. DeMarco C., Invernizzi G., Miceli R., Mariani L., VillariniA., Munarini E., Mazza R., Boffi R. Breast changeperception in women after smoking cessation. Apilot study. Tumori. 2011; 97: 672-5.

Contributions

Consensus document: Il tabagismo in Italia -Interventi per la smoking-cessation: il ruolo dellafarmacoterapia (Istituto Superiore di Sanità 2011)http://www.iss.it/fumo/publ/cont.php?id=263&lang=1&tipo=19

142Shared Research Resources

clinical psychology

HEAD Claudia Borreani, Psy D

CLINICAL RESEARCH STAFFMarco Bosisio, Psy D Margherita Greco, Psy D Micaela B. Lina, Psy D Luciana Murru, Psy D Patrizia Trimigno, Psy D Laura Gangeri, PsycoPedagogist Silvia Bettega, Social Worker

FELLOW Elisabetta Bianchi, PsyD

STATISTICIANCinzia Brunelli

ADMINISTRATIVE PERSONNELTeresa Maria Cariglia

The Clinical Psychology Unit addresses the psychologicaland social aspects of patients with cancer. PsychOncologylooks at the whole range of mental and emotional issuesrelated to cancer, in the context of the patient’s lifebefore, during, and after diagnosis and treatment. Helpingclinicians to know when patients need emotional supportis another part of PsychOncology’s mission. The clinicalactivity includes: psychological assessment, individual psy-chological counseling, short psychotherapies, familytherapies, and psycho-educational groups. During 2011,the following psycho-educational groups were carriedout: a) the Ulysses program, which involves patients andtheir relatives in educational and psychological supportgroups; b) stress management training and relaxationimagery groups; c) touch therapy groups; d) meaning ori-ented groups. “Ambulatorio Giocoparola” created withthe aim to give ill parents a support in the communica-

tion with their children about the disease, continued itsactivity. Collaboration with other Clinical Units on specificissues includes: • Multidisciplinary clinical project to sup-port cancer patients undergoing liver transplant incollaboration with the Transplantation Unit. • Multidiscipli-nary clinical project to support decision-making inBRCA1/2 carriers in collaboration with Medical GeneticsUnit • Clinical decision making counseling, psychologicalsupport, and psycho-sexual counseling for prostate can-cer patients in collaboration with Prostate Program • Themultidisciplinary smoking cessation project for inpatientsin collaboration with the Tobacco Control Unit. Theresearch activity of the Unit is mainly oriented to theevaluation of subjective impact of cancer and treatmentson patients’ quality of life and the psychosocial aspectsrelated to the different phases of oncological disease. Keywords: psychoncology, psychological support, quality of life

RELEVANT NOTES

Collaborations

Dipartimento di Psicologia dell’Università degliStudi di Milano-Bicocca. Istituto per lo Studio e laPrevenzione Oncologica (ISPO), Florence Unità diNeuro Epidemiologia Fondazione IRCCS IstitutoNeurologico C. Besta, Milan

Publications

Mazza R, Lina M, Invernizzi G, Pierotti M, De MarcoC, Borreani C, Boffi R. The gap between tobaccotreatment guidelines, health service organization,

and clinical practice in comprehensive cancercentres. J Oncol. 2011; 2011: 145617. Borreani C,Giordano A, Falautano M, Lugaresi A, Martinelli V,Granella F, Tortorella C, Plasmati I, Radaelli M,Farina D, Bella ED, Bianchi E, AcquaroneN,Miccinesi G, Solari A; on behalf of the SIMS-Trialgroup. Experience of an information aid for newlydiagnosed multiple sclerosis patients: a qualitativestudy on the SIMS-Trial. Health Expect. 2011 Nov1. doi:10.1111/j.1369-7625.2011.00736.x.

143 Scientific Report 2011

medical statistics, biometry, and bioinformatics

HEAD Adriano Decarli, PhD

RESEARCH STAFF Elia Biganzoli, PhD Sara Pizzamiglio, MSCPaolo Verderio, Biol Sci D, PhD

ADMINISTRATIVE PERSONNELMaria Chiara Piano

POSTDOCTORAL FELLOWSIlaria Ardoino, PhD Matteo Malvezzi, PhD

PHD STUDENTS Nicola BassaniAnnalisa Orenti

FELLOWChiara Maura Ciniselli, MSC

The Medical Statistics Biometry and Bioinformatics Unit(MSBB) provides quantitative support to development ofthe research activity of INT. Moreover, MSBB bridges col-laborative relationships with other national orinternational research groups. The INT group activity isgoverned by the convention with the University of Milan.Areas of method development and application pertinentto MSBB activity include assay development and qualitycontrol, predictive models for diagnosis and prognosis,plan and design of observational or randomized studies,data management and study monitoring, and techniquesto report and interpret the results of clinical studies. Themain topics in epidemiological research are the relation-ships between dietary habits and risk of cancer, toimplement innovative statistical multivariate models in theanalysis of dietary data, and to develop predictive modelsfor cancer risk. Biostatistics for Oriented Basic Researchand Quality Control (Paolo Verderio) The team appliesstatistical methods to different phases of the biomarkerdevelopment process in oncology. Specifically, it provides

implementation and statistical analysis of quality controlstudies for tumor biomarkers and in vitro-diagnostictools; studies for the evaluation of inherited diseases inoncology; studies for setting up and validation of biologi-cal assays; studies of preclinical pharmacology and studiesfor testing new molecular detection strategies based oninnovative technologies. Biostatistics for Bioinformatics and Translational Research(Elia M. Biganzoli) The team follows the transfer of basicpreclinical research to the clinical setting, resorting toquantitative approaches for the assessment of the impactof new technologies in oncology, according to cost-bene-fit principles and sustainability perspectives. Collaborativeprojects are related to the comparison of different high-throughput and next generation sequencing platforms forRNA analysis, qRT-PCR, and high throughput assays incancer. Keywords: risk prediction methods, high dimensional data methods,

oncological biomarkers

RELEVANT NOTES

Collaborations

International Agency for Research in Cancer(IARC), Lyon, France Biostatistics Branch, NationalCancer Institute, Bethesda, USA Molecular andNutritional Epidemiology Unit , ISPO Florence, ItalyISS-ACC Bioinformatics Oncology NetworkRNBIO INNS Biopattern Special Interest GroupItalian Network for Quality Assessment of TumorBiomarkers (INQAT) SPIDIA – European Project -7th FP: Standardisation and improvement ofgeneric pre-analytical tools and procedures for invitro diagnostics PIO project - Italian Ministry ofHealth:Analytical and clinical validation of newbiomarkers for early diagnosis: the Network, theresources, the methodology, the QC, the analysis ofdata. AB Analitica s.r.l.: Programma di verificaesterna di qualità (VEQ) in biologia molecolareAIRC projects : “Novel approaches for theassessment of the functional effects of unclassifiedvariants in BRCA genes”; Translating innovation

into colorectal cancer control”. Ricerca Finalizzata2009 : “Cerebrospinal fluid proteome from CentralNervous System pediatric tumors: patient relatedpattern” Collaborations with the following nationaland international working groups: CIMBA, EFCC,SIBIOC,ROL

Publications

Casarsa C, Bassani N, Ambrogi F, Zabucchi G,Boracchi P, Biganzoli E, Coradini D. Epithelial-to-mesenchymal transition, cell polarity andstemness-associated features in malignant pleuralmesothelioma. Cancer Lett. 2011; 302: 136-43.Catucci I, Verderio P, Pizzamiglio S, Manoukian S,Peissel B, Zaffaroni D, Roversi G, Ripamonti CB,Pasini B, Barile M, Viel A, Giannini G, Papi L, VarescoL, Martayan A, Riboni M, Volorio S, Radice P,Peterlongo P. The CASP8 rs3834129polymorphism and breast cancer risk in BRCA1mutation carriers. Breast Cancer Res Treat. 2011;125: 855-60. Petracci E., Decarli A., Schairer C.,Pfeiffer R.M., Pee D, Masala G, Palli D., Gail M.H. Risk

Factor Modification and Projections of AbsoluteBreast Cancer Risk. J Natl Can Inst. 2011; 103:1037-48.

Contributions

Paolo Verderio is member of the Editorial Board ofthe Journal of Clinical Oncology. Paolo Verderioand Sara Pizzamiglio are members of the “SocietàItaliana di Statistica Medica ed EpidemiologiaClinica” (SISMEC). Elia Biganzoli is member of theEditorial Board of Source Code in Biology andMedicine. He was the chairman of the internationalconference Computational Intelligence forBioinformatics and Biostatistics CIBB 2011 inGargnano del Garda. Adriano Decarli is member ofthe Epidemiology Working Group of theInternational Society of Clinical Biostatistics (ISCB),President of the Biometric Society (Italian Region).AD and EB are members of the OrganizingCommettee of International Biometric SocietyCongress (Florence, 2014)

144

HEAD Luigi Mariani, MD, PhD

RESEARCH STAFFRosalba Miceli, PhD

TECHNICIANSalvatore Lo Vullo, BSc

ADMINISTRATIVE PERSONNELMaria Chiara Piano

Clinical Epidemiology and Trial OrganizationAn overall number of 126 projects were run (mainly inthe areas of surgical, medical or hematologic oncology), ofwhich 80 were activated during the year. A total of 17articles were published. Keywords: biostatistics, study design, data analysis

RELEVANT NOTES

Publications

Mazzaferro V., Bhoori S., Sposito C., Bongini M., LangerM., Miceli R., Mariani L. Milan criteria in livertransplantation for HCC: an evidence-based analysis on15 years of experience. Liver Transplant. 2011; 17(S2):44-57. Scarpi E., Maltoni M., Miceli R., Mariani L.,Caraceni A., Amadori D., Nanni O. Survival predictionfor terminally ill cancer patients: revision of the palliativeprognostic score with incorporation of delirium.Oncologist. 2011; 16: 1793-9.

Shared Research Resources

medical statistics, biometry, and bioinformatics

tissue bank

DIRECTORS Giuseppe Pelosi, MDMaria Grazia Daidone, Biol Sci D, PhD

RESEARCH STAFF Silvia Veneroni, Biol Sci D

TECHNICIANSFrancesco PastoreGloria Morandi

Since 2002, the Tissue Bank Facility of the INT has beendedicated to the collection and distribution of neoplastic,preneoplastic, and normal tissues from human subjectsfor research projects. This resource is a project of INTScientific Directorate, with day-to-day staff supervisionprovided by personnel from the Departments of Pathol-ogy and Experimental Oncology & Molecular Medicine.The activities are overseen by an interdepartment advi-sory committee, which also evaluates and approvesresearch projects depending on the availability of tissuespecimens. Adopting TUBAFROST procedures, althoughslightly modified to comply with local conditions, the INTTissue Bank stores frozen samples (primary and metasta-tic lesions, with corresponding normal tissues) andcontributes specimens to more than 30 specific researchprojects dealing with breast, ovarian, lung, head and neck,thyroid, colorectal, endometrial, and renal cancers, in addi-tion to soft tissue sarcomas, melanoma, and pediatrictumors.All patients/subjects sign an informed consent document(approved by the Independent Ethics Committee andfiled in the patients’ record) to donate the leftovertissue/biological specimens after diagnostic procedureshave been completed for future studies at the INT TissueBank. It is a one-time general consent using a two stepdecision simplifying procedure, that might allow patientsto control the use of their samples and foster importantresearches. At the time of surgical and/or medical proce-dures, patients are told how samples and healthinformation will be obtained, what risks future researchuses pose to them, and whether the research will haveany impact on their clinical care. They can choosewhether their samples and associated information may or

may not be used for future research, relying on an Inde-pendent Ethics Committee for the approval of biologicallyand/or clinically relevant studies. Otherwise, patients willbe contacted repeatedly to provide study specific author-ization for the use of biological samples and associatedpersonal information. Guidelines have been proposed todefine responsibilities for Tissue Bank management, poli-cies, and procedures to protect patient confidentiality andprivacy, and establish priorities for specimen distribution.A survey carried out on about 3000 inform consentforms showed that reliable and consistent responseswere obtained in 80% of the cases: 95& of the patientssupport the future research use of their biological sam-ples, with a request to be repeatedly contacted in only3% of the cases. In collaboration with the INT Division of InformationTechnology an integrated data base is now under imple-mentation to link information related to biospecimens topathologic diagnosis, minimum clinical data set, and fol-low-up and to allow a dynamic and user-friendly interfacefor pre-clinical and clinical studies.In 2011, the INT Tissue Bank stored frozen specimensfrom 1190 new cases. Investigations are currently ongoingto assess the routine feasibility of a formalin-free samplecollection method based on a 4°C under-vacuum preser-vation of tissue specimens from surgical removal toprocessing for sampling and biobanking and its reliabilityin preserving RNA integrity, gene expression, phospho-proteomic and metabolomic profiles. Pre-processingconditions between surgery and freezing of samplesappear to have a strong impact on sample quality andshould be considered as a mandatory variable to controlfor clinical implications of inadequate tissue handling.

145 Scientific Report 2011

functional genomics and bioinformatics core facility

HEADSilvana Canevari, Bio Sci D

RESEARCH STAFF Marina Bagnoli, Biol Sci D,Vera Cappelletti, Biol Sci DLoris De Cecco, Biol Sci DRosaria Orlandi, Biol Sci DMaria Luisa Sensi, Biol Sci D

POSTDOCTORAL FELLOWSMaurizio Callari, Biotech D, BioinformaticianGaetano De Feo, Biol Sci DMatteo Dugo, Biotech D, BioinformaticianPatrizia Pinciroli, Biol Sci D

TECHNICIANSEdoardo MarchesiDonata Penso

The activities of the Functional Genomics and Bioinfor-matics core facility are based on wet analyses performedusing the Illumina and Agilent platforms andcomputational analyses using dedicated workstations. Theresearch group comprises full time personnel involved inwet analyses and personnel dedicating part of their insti-tutional activity to computational analysis of wet and insilico data.The core facility takes care of: study design; RNA andDNA extraction and quality controls; all the labeling andhybridization methodologies required for high qualityanalysis; data processing and normalization. Full computa-tional analyses are performed using Software opensource (such as R-Bioconductor, BRB, GSEA, MAGIA) anddedicated licenses (such as IPA for candidate proteininteractions, Gene Spring, Genomic Workbench). Compu-tational biofunctional interpretation of promising

biomarkers are based on: Correlation Analysis, GeneOntology, Gene Set Enrichment Analysis, and Predictionof miRNA targets. During 2011, more than 2000 samples arising fromexperimental and clinical studies were analyzed for : wholegenome expression; Illumina DASL (cDNA-mediatedannealing, selection, extension and ligation) assay; miRNAwhole expression. Furthermore, the core facility staff: set-up specificmethodologies for efficient extraction and quality controlof nucleic acids from archival materials such asheparinated plasma and formalin fixed paraffin embeddedsamples; made methodological comparison of differentmiRNA platforms; elaborated in silico analyses using pub-licly available datasets; participated to the information andformation of the personnel with dedicated seminars.

RELEVANT NOTES

Collaborations

Dr Giovanna Chiorino, Fondazione Edo ed ElvoTempia, Biella

Dr Silvano Ferrini, IST Genova

Publications

Bagnoli M, De Cecco L, Granata A, Nicoletti R,Marchesi E, Alberti P, Valeri B, Libra M, BarbareschiM, Raspagliesi F, Mezzanzanica D, Canevari S.

Identification of a chrXq27.3 microRNA clusterassociated with early relapse in advanced stageovarian cancer patients. Oncotarget. 2011Dec;2(12):1265-78.

Sommariva M, De Cecco L, De Cesare M,Sfondrini L, Ménard S, Melani C, Delia D, ZaffaroniN, Pratesi G, Uva V, Tagliabue E, Balsari A. TLR9agonists oppositely modulate DNA repair genes intumor versus immune cells and enhancechemotherapy effects. Cancer Res. 2011 Oct15;71(20):6382-90.

146Shared Research Resources

cancer proteomics - molecular mechanisms

HEADItalia Bongarzone, Biol Sci D

POSTDOCTORAL FELLOWSCaccia Dario, Biotech D, PhDElena Vaghi, Biotech D, PhDRuben Magni, Biotech D, PhD

TECHNICIANMaida De Bortoli

The laboratory continues to develop progressive meth-ods for the discovery of biomarkers. Thesedevelopments include evaluation of proteins for quantita-tive studies, methods to measure proteins in cell lines,tissue biopsies, and dual tissue/biofluid analysis for moreconfident biomarker discovery. Our main interest is the tumor microenvironmentbecause of its role in growth and metastasis. The tumormicroenvironment can be defined as the insoluble ele-ments of the extracellular matrix, the stroma with itscellular elements such as fibroblasts and immune cells andthe fluid phase of dissolved substances. Traditionally thefocus has been on the stroma and the cellular elementsof the tumor, whereas we focus on the fluid phase thatmay be thought as a “misconsidered component of theinternal milieu of a solid tumor”.Mass spectrometry techniques combined with bioinfor-matics allow detection, identification and quantification of

numerous peptides and proteins in biological samples.This offers new avenues for detection of tumor-specificbiomarkers may be important for detection of risk, earlydisease and response to treatment. Other sources usedfor biomarkers are cerebrospinal fluid and urine that canbe sampled noninvasively and in addition toplasma/serum. Ongoing projects:• regulation of iron metabolism in breast cancer• renal cancer stratification for anticancer strategies• signaling pathway profiling of colorectal cancer livermetastases for targeted therapy• cerebrospinal fluid proteome from central nervoussystem pediatric tumors: patient-related patterns.Keywords: mass spectrometry, cancer biomarkers, human fluids,

signaling pathways, targeted therapy

RELEVANT NOTES

Technologies

1-D and 2-D electrophoretic protein separations,DIGE technology,

MALDI-TOF mass spectrometry (Voyager DE-STR), and SELDI-TOF technology (PCS 4000)

Collaborations

Istituto Superiore di Sanità

Istituto Nazionale per la Ricerca sul Cancro (IST),Genoa

IRCCS Ospedale Oncologico, Bari

IRCCS S. Maria Nuova, Reggio Emilia

Applied Biology at the University of Brescia

George Mason University, Center for AppliedProteomics and

Molecular Medicine, Virginia, USA

Laboratori d'Investigació UdL/HUAV Dept.Medicina Experimental

Universitat de Lleida, Spain

Publications

Vergani E, Vallacchi V, Frigerio S, Deho P, MondelliniP, Perego P, Cassinelli G, Lanzi C, Testi MA, RivoltiniL, Bongarzone I, Rodolfo M. Identification of METand SRC activation in melanoma cell lines showingprimary resistance to PLX4032. Neoplasia. 2011Dec;13(12):1132-42.

Da Riva L, Bozzi F, Mondellini P, Miccichè F,Fumagalli E, Vaghi E, Tarantino E, Huber V, GronchiA, Tamborini E, Pierotti MA, Pilotti S, Bongarzone I.Proteomic detection of a large amount of SCGF�in the stroma of GISTs after imatinib therapy. JTransl Med. 2011 Sep 23;9:158.

Zappasodi R, Bongarzone I, Ghedini GC, CastagnoliL, Cabras AD, Messina A, Tortoreto M, Tripodo C,Magni M, Carlo-Stella C, Gianni AM, Pupa SM, DiNicola M. Serological identification of HSP105 as anovel non-Hodgkin lymphoma therapeutic target.Blood. 2011 Oct 20;118(16):4421-30.

Caccia D, Zanetti Domingues L, Miccichè F, DeBortoli M, Carniti C, Mondellini P, Bongarzone I.Secretome compartment is a valuable source ofbiomarkers for cancer-relevant pathways. JProteome Res. 2011 Sep 2;10(9):4196-207.

Miccichè F, Da Riva L, Fabbi M, Pilotti S, MondelliniP, Ferrini S, Canevari S, Pierotti MA, Bongarzone I.Activated leukocyte cell adhesion moleculeexpression and shedding in thyroid tumors. PLoSOne. 2011 Feb 22;6(2):e17141.

Nicolini V, Cassinelli G, Cuccuru G, Bongarzone I,Petrangolini G, Tortoreto M, Mondellini P, Casalini P,Favini E, Zaffaroni N, Zunino F, Lanzi C. Interplaybetween Ret and Fap-1 regulates CD95-mediatedapoptosis in medullary thyroid cancer cells.Biochem Pharmacol. 2011 Oct 1;82(7):778-88.

Borrello MG, Aiello A, Peissel B, Rizzetti MG,Mondellini P, Degl'Innocenti D, Catalano V, GobboM, Collini P, Bongarzone I, Pierotti MA, Greco A,Seregni E. Functional characterization of the MTC-associated germline RET-K666E mutation: evidenceof oncogenic potential enhanced by the G691Spolymorphism. Endocr Relat Cancer. 2011 Jul25;18(4):519-27.

Garrisi VM, Bongarzone I, Mangia A, Cremona M,De Bortoli M, Vaghi E, Galetta D, Pastorino U,Quaranta M, Abbate I, Paradiso A. Characterizationof a serum protein pattern from NSCLC patientstreated with Gefitinib. Clin Biochem. 2011Jul;44(10-11):936-40.

147 Scientific Report 2011